CSF3 and inflammatory bowel disease: We started an “off‐label” EMPA treatment because of recurrent infections, low neutrophil count, and lack of inflammatory bowel disease remission on G‐CSF (2.5 μg/kg/24 h) and mesalazine (40 mg/kg/day).